Prevalence of arterial hypertension and the number and classes of antihypertensive drugs prescribed for patients late after kidney transplantation

Annals of Transplantation

Volumn 17, Issue 1, 2012, Pages 50-57

  Kurnatowska, Ilona ^a   Królikowski, Jerzy ^a   Jesionowska, Kinga ^a   Marczak, Anna ^a   Krajewska, Joanna ^a   Zbróg, Zbigniew ^b   Nowicki, Michał ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b M Kopernik Hospital   (Poland)

Author keywords

Antihypertensive agents; Arterial hypertension; Kidney transplantation

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CLONIDINE; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; FEMALE; HUMAN; HYPERTENSION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PREVALENCE; RENAL GRAFT DYSFUNCTION;

EID: 84859393012     PISSN: 14259524     EISSN: None     Source Type: Journal    
DOI: 10.12659/aot.882636     Document Type: Article

References (45)

1. Paoletti E, Gherzi M, Amidone M et al: Association of arterial hypertension with renal target organ damage in kidney transplant recipients: the predictive role of ambulatory blood pressure monitoring. Transplantation, 2009; 87: 1864-69
2. El-Agroudy AE, Bakr MA, Shehab El-Dein AB, Ghoneim MA: Death with functioning graft in living donor kidney transplantation: analysis of risk factors. Am J Nephrol, 2003; 23: 186-93
3. Kasiske BL, Anjum S, Shah R: Hypertension after kidney transplantation. Am J Kidney Dis, 2004; 43: 1071-81
4. Ponticelli C, Cucchiari D, Graziani G: Hypertension in kidney transplant recipients. Transpl Int, 2011; 24: 523-33
5. Opelz G, Wujciak T, Ritz E: Association of chronic kidney graft failure with recipient blood pressure. Kidney Int, 1998; 53: 217-22
6. Wadei HM, Textor SC: Hypertension in the kidney transplant recipient. Transplant Rev, 2010; 24: 105-20
7. Law MR, Morris JK, Wald NJ: Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ, 2009; 338: b1665
8. Opelz G, Dohler B, Collaborative Transplant Study: Improved long-term outcomes after renal transplantation associated with blood pressure control. Am J Transplant, 2005; 5: 2725-31
9. Kasiske B, Zeier MG, Chapman JR et al: KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int, 2010; 77: 299-311
10. Rike AH, Mogilishetty G, Alloway RR et al: Cardiovascular risk, cardiovascular events, and metabolic syndrome in renal transplantation: comparison of early steroid withdrawal and chronic steroids. Clin Transplant, 2008; 22: 229-35
11. Mangray M, Vella J: Hypertension after kidney transplant. Am J Kidney Dis, 2011; 57: 331-41
12. Levey AS, Bosch JP, Lewis JB et al: Modification of Diet in Renal Disease Study Group: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med, 1999; 130: 461-70
13. Małyszko J, Małyszko J, Bachorzewska-Gajewska H et al: Inadequate blood pressure control in most kidney transplant recipients and patients with coronary artery disease with and without complications. Transplant Proc, 2009; 41: 3069-72
14. Małyszko J, Małyszko J, Bachorzewska-Gajews ka H et al: Inadequate blood pressure control in vast majority of kidney allograft recipients and patients with coronary artery disease with and without comorbidities. Ann Transplant, 2009; 14 (Suppl.1): 49
15. Pilmore HL, Skeans MA, Snyder JJ et al: Cardiovascular disease medications after renal transplantation: results from the patient outcomes in renal transpalntation study. Transplantation, 2011; 91: 542-51
16. Karthikeyan V, Karpiński J, Nair RC, Knoll G: The burden of chronic kidney disease in renal transplant recipients. Am J Transplant, 2004; 4: 262-69
17. Tutone VK, Mark PB, Stewart GA et al: Hypertension, antihypertensive agents and outcomes following renal transplantation. Clin Transplant, 2005; 19: 181-92
18. Rodicio JL: Calcium antagonists and renal protection from cyclosporine nephrotoxicity: longterm trial in renal transplantation patients. J Cardiovasc Pharmacol, 2000; 35: S7-11
19. Cross NB, Webster AC, Masson P et al: Antihypertensives for kidney transplant recipients: systematic review and meta-analysis of randomized controlled trials. Transplantation, 2009; 88: 7-18
20. Ruggenenti P, Perico N, Monsconi L et al: Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion. Kidney Int, 1993; 43: 709-11
21. Jennings DL, Taber DJ: Use of rennin-angiotensin- aldosteron system inhibitors within the first eight to twelve weeks after transplantation. Ann Pharmacother, 2008; 42: 116-20
22. Pradhan S, Mishra P: Gingival enlargement in antihypertensive medication. JNMA J Nepal Med Assoc, 2009; 48: 149-52
23. Furberg CD, Psaty BM, Meyer JV: Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation, 1995; 92: 1326-31
24. Kasiske BL, Chakkera H, Roel J: Explained and unexplained icheamic heard disease risk after renal transplantation. J Am Soc Nephrol, 2000; 11: 1735-43
25. Lindholm A, Henricsson S: Verapamil inhibits cyclosrine metabolism. Lancet Lancet, 1987; 1: 1262-63
26. Pesavento TE, Jones PA, Julian BA, Curtis JJ: Amlodipine increases cyclosporine levels in hypertensive renal transplant patients. Results of prospective study. J Am Soc Nephrol, 1996; 7: 831-35
27. Cai J, Huang Z, Yang G et al: Comparing antihypertensive effect and plasma ciclosporin concentration between amlodipine and valsartan regimens in hypertensive renal transplant patients receiving ciclosporin therapy. Am J Cardiovasc Drugs, 2011; 11: 401-9
28. Hackam DG, Khan NA, Hemmelgarn BR et al: The 2010 Canadian Hypertension Education Program recommendations for management of hypertension: part 2-therapy. Can J Cardiol, 2010; 26: 249-58
29. Fonseca VA: Effects of beta-blockers on glucose and lipid metabolism. Curr Med Res Opin, 2010; 26: 615-29
30. Mancia G, Laurent S, Agabiti-Rosei E et al: Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens, 2009; 27: 2121-58
31. Nash DT: Alpha-adrenergic blockers: mechanism of action, blood pressure control, and effects of lipoprotein metabolism. Clin Cardiol, 1990; 13: 764
32. Shirali AC, Bia MJ: Management of cardiovascular disease in renal transplant recipients. Clin J Am Soc Nephrol, 2008; 3: 491-504
33. Mourad G, Ribstein J, Mimran A: Convertingenzyme inhibitor versus calcium antagonist in cyclosporine-treated renal transplants. Kidney Int, 1993; 43: 419-25
34. Holgado R, Anaya F, Del Castillo D: Angiotensin II type 1 (AT1) receptor antagonists in the treatment of hypertension after renal transplantation. Nephrol Dial Transplant, 2001; 16: 117-20
35. Hiremath S, Fergusson D, Doucette S et al: Renin angiotensin system blockade in kidney transplantation: a systemic review of the evidence. Am J Transplant, 2007; 7: 2350-60
36. Vlahakos DV, Canzanello VJ, Madaio MP, Madias NE: Enerapril-associated anemia in renal transplant recipients treated for hypertension. Am J Kidney Dis, 1991; 17(2): 199-205
37. Heinze G, Collins S, Benedict MA et al: The association between angiotensin converting enzyme inhibitor or angiotensin receptor blocker use during postischemic acute transplant failure and renal allograft survival. Transplantation, 2001; 72: 1787
38. Yusuf S, Sleight P, Pogue J et al: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N Engl J Med, 2000; 342: 145-53
39. Ruggenenti P, Perna A, Gherardi G et al: Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet, 1998; 352(9136): 1252-56
40. Locatelli F, Carbarns IR, Maschio G et al: Longterm progression of chronic renal insufficiency in the AIPRI Extension Study. The Angiotensin- Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Kidney Int Suppl, 1997; 63: S63-66
41. Schweitzer E, Matas AJ, Gilingham KG et al: Cause of renal allograft loss. Progress in the 1980s, challenges for the 1990s. Ann Surg, 1991; 214: 679-88
42. Erdogan D, Gullu H, Caliskan M et al: Relationship of serum uric acid to measures of endothelial function and atherosclerosis in healthy adults. Int J Clin Pract, 2005; 59: 1276-82
43. Hoorn EJ, Walsh SB, McCormick JA et al: The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension. Nat Med, 2011; 17: 1304-9
44. Jardine AG, Gaston RS, Fellstrom BC, Holdaas H: Prevention of cardiovascular disease in adult recipients of kidney transplants. Lancet, 2011; 378: 1419-27
45. Chatzikyrkou C, Menne J, Gwinner W et al: Pathogenesis and management of hypertension after kidney transplantation. J Hypertens, 2011; 29: 2283-94